Literature DB >> 3462334

Endogenous sleep-substances and sleep regulation.

A A Borbély.   

Abstract

In the search for endogenous sleep substances two approaches can be distinguished. The homeostatic approach assumes that the sleep substance accumulates during waking and dissipates during sleep. Sleep deprivation has been the principal tool for enhancing the level of a sleep substance in a donor animal before testing its hypnogenic effect in a recipient animal. Among the two sleep factors isolated by this approach, Factor S has been identified as a muramyl peptide, whereas the composition of Sleep Promoting Substance (SPS) has not yet been fully clarified. Recently, factors have been obtained from REM sleep deprived donors which are able to antagonize drug-induced REM sleep suppression in recipients. The homeostatic approach can be related to physiological processes underlying sleep homeostasis and circadian rhythms. The non-homeostatic approach to sleep substances is based on the serendipitous discovery of a hypnogenic action. While a number of such substances have been described, their relationship to physiological sleep regulation is unknown. Melatonin has been reported to induce or enhance sleep in animals and man. However, the doses used in human studies raise the plasma level far beyond the physiological range. Melatonin may influence circadian processes regulating sleep propensity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462334

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  2 in total

1.  The influence of the delta-sleep-inducing peptide on convulsive activity.

Authors:  A A Shandra; L S Godlevskii; A M Mazarati; A A Oleshko; I I Mikhaleva
Journal:  Neurosci Behav Physiol       Date:  1993 Sep-Oct

2.  Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders.

Authors:  Kotaro Yuge; Shinichiro Nagamitsu; Yuko Ishikawa; Izumi Hamada; Hiroyuki Takahashi; Hideyuki Sugioka; Osamu Yotsuya; Kazuo Mishima; Masaharu Hayashi; Yushiro Yamashita
Journal:  BMC Psychiatry       Date:  2020-09-10       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.